Anaptys Announces Participation in September Investor Conferences
August 29, 2024 09:15 ET
|
AnaptysBio, Inc.
SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
August 14, 2024 05:00 ET
|
AnaptysBio, Inc.
SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the...
Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update
August 05, 2024 16:15 ET
|
AnaptysBio, Inc.
Top-line data expected in December 2024 after having completed enrollment for Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonistTop-line data accelerated and now anticipated...
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024 16:15 ET
|
AnaptysBio, Inc.
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024Enrollment ongoing for global Phase 2b...
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
May 09, 2024 16:10 ET
|
AnaptysBio, Inc.
All eight patients from GEMINI-1 who responded to a single intravenous (IV) imsidolimab dose and were subsequently re-randomized to monthly subcutaneous (SC) maintenance dosing of imsidolimab in...
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties
May 09, 2024 16:05 ET
|
AnaptysBio, Inc.
Anaptys to receive $50 million upfront cash payment from Sagard HealthcarePrior agreement amended to now expire once Sagard receives a capped payoff of either $600 million if received by March 31,...
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 11, 2024 16:15 ET
|
AnaptysBio, Inc.
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist, with top-line data anticipated by year-end 2024Enrollment ongoing for global Phase 2b trial...
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
February 29, 2024 09:15 ET
|
AnaptysBio, Inc.
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
January 31, 2024 09:15 ET
|
AnaptysBio, Inc.
SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
November 27, 2023 16:15 ET
|
AnaptysBio, Inc.
Anaptys licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfolioIND filing to support clinical development of ANB101 in autoimmune and...